A recent clinical experiment has shown that administering a high dosage of immunosuppressive therapy followed immediately by a transplantation of human stem cells that produce blood will lead to a sustained decrease of relapse remitting multiple sclerosis. Sclerosis is an autoimmune ailment in which your own immune system attacks the nervous system.
Dr. Shiva Gopal, the managing director and principle investigator of HALT-MS study, said that this five-year research had given promise and insight into the treatment of the disease. From the few individuals who were subjected to the treatment, seventy percent of the people had fully survived without going through new brain lesions, the progression of disability and relapse of multiple sclerosis symptoms. It is more impressive if you consider that none of the participants took any multiple sclerosis medications after finishing the process.
The trial was fully sponsored by NIAID (National Institute of Allergy and Infectious Diseases). The initial three-year results were published in December 2014 and the comprehensive five years results were availed at the start of the year. Multiple sclerosis symptoms include weakness, fatigue, motor difficulties, speech difficulties and chronic pain. Researchers also tested the durability, safety and efficacy of the treatment by using volunteers aged between twenty-six and fifty-two with relapse remitting multiple sclerosis. The volunteers had previously taken available medications but experienced reactions like frequent severe relapses, active inflammation and neurological disability.
National Institute of Health is the countries medical research agency. It has a total of twenty-seven centers and institutes and is a section of the United States Department of Health and Human Services. It focuses on the research and prevention of common and rare diseases treatment.